Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 34
Encontrada(s) 1 página(s)

Biblos-e Archivo. Repositorio Institucional de la UAM
Publication Artículo científico (JournalArticle)

Impaired mitochondrial oxidative phosphorylation in the peroxisomal disease X-linked adrenoleukodystrophy

  • López-Erauskin, J.
  • Galino, J.
  • Ruiz, M.
  • Cuezva Marcos, José Manuel
  • Fabregat, I.
  • Cacabelos, D.
  • Boada, J.
  • Martínez, J.
  • Ferrer, I.
  • Pamplona, R.
  • Villarroya, Fransesc
  • Portero-Otín, M.
  • Fourcadeand, S.
  • Pujol, A.
This is a pre-copyedited, author-produced PDF of an article accepted for publication in Human Molecular Genetics following peer review. The version of record Human Molecular Genetics 22.16 (2013): 3296-3305 is available online at http://hmg.oxfordjournals.org/cgi/pmidlookup?view=long&pmid=23604518, X-linked adrenoleukodystrophy (X-ALD) is an inherited metabolic disorder of the nervous system characterized by axonopathy in spinal cords and/or cerebral demyelination, adrenal insufficiency and accumulation of very long-chain fatty acids (VLCFAs) in plasma and tissues. The disease is caused by malfunction of the ABCD1 gene, which encodes a peroxisomal transporter of VLCFAs or VLCFA-CoA. In the mouse, Abcd1 loss causes late onset axonal degeneration in the spinal cord, associated with locomotor disability resembling the most common phenotype in patients, adrenomyeloneuropathy. We have formerly shown that an excess of the VLCFA C26:0 induces oxidative damage, which underlies the axonal degeneration exhibited by the Abcd1(-) mice. In the present study, we sought to investigate the noxious effects of C26:0 on mitochondria function. Our data indicate that in X-ALD patients' fibroblasts, excess of C26:0 generates mtDNA oxidation and specifically impairs oxidative phosphorylation (OXPHOS) triggering mitochondrial ROS production from electron transport chain complexes. This correlates with impaired complex V phosphorylative activity, as visualized by high-resolution respirometry on spinal cord slices of Abcd1(-) mice. Further, we identified a marked oxidation of key OXPHOS system subunits in Abcd1(-) mouse spinal cords at presymptomatic stages. Altogether, our results illustrate some of the mechanistic intricacies by which the excess of a fatty acid targeted to peroxisomes activates a deleterious process of oxidative damage to mitochondria, leading to a multifaceted dysfunction of this organelle. These findings may be of relevance for patient management while unveiling novel therapeutic targets for X-ALD, This study was supported by grants from the European Commission (FP7-241622), the European Leukodystrophy Association (ELA2009-036C5; ELA2008-040C4), the Spanish Institute for Health Carlos III (FIS PI080991 and FIS PI11/01043), the Autonomous Government of Catalonia (2009SGR85) to A.P. and the Spanish Institute for Health Carlos III (Miguel Servet program CP11/00080) to S.F. The CIBER on Rare Diseases (CIBERER) is an initiative of the ISCIII. The study was developed under the COST action BM0604 (to A.P.). J.L.-E. was a fellow of the Department of Education, Universities and Research of the Basque Country Government (BFI07.126). S.F. was a fellow of the European Leukodystrophy Association (ELA 2010-020F1). The studies conducted at the Department of Experimental Medicine were supported in part by R&D grants from the Spanish Ministry of Science and Innovation (BFU2009-11879/BFI), the Spanish Ministry of Health (PI11/1532), the Autonomous Government of Catalonia (2009SGR735), the ‘La Caixa’ Foundation and COST B35 Action of the European Union. D.C. is a fellow from the Spanish Ministry of Health (FI08-00707). The studies conducted at the Department of Biochemistry and Molecular Biology, University of Barcelona, were supported by grants SAF2008-01896 and SAF2011-23636 from the Spanish Ministry of Science and Innovation
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Modulation of mitochondrial and inflammatory homeostasis through RIP140 is neuroprotective in an adrenoleukodystrophy mouse model

  • Ranea-Robles, Pablo
  • Galino, Jorge
  • Espinosa Blay, Lluís
  • Schlüter, Agatha
  • Ruiz, Montserrat
  • Calingasan, Noel Ylagan
  • Villarroya, Francesc
  • Naudí, Alba
  • Pamplona, Reinald
  • Ferrer, Isidre
  • Beal, M. Flint
  • Portero Otín, Manuel
  • Fourcade, Stéphane
  • Pujol, Aurora, 1968-
Aims: Mitochondrial dysfunction and inflammation are at the core of axonal degeneration in several multifactorial neurodegenerative diseases, including multiple sclerosis, Alzheimer's disease, and Parkinson's disease. The transcriptional coregulator RIP140/NRIP1 (receptor-interacting protein 140) modulates these functions in liver and adipose tissue, but its role in the nervous system remains unexplored. Here, we investigated the impact of RIP140 in the Abcd1- mouse model of X-linked adrenoleukodystrophy (X-ALD), a genetic model of chronic axonopathy involving the convergence of redox imbalance, bioenergetic failure, and chronic inflammation. Methods and results: We provide evidence that RIP140 is modulated through a redox-dependent mechanism driven by very long-chain fatty acids (VLCFAs), the levels of which are increased in X-ALD. Genetic inactivation of RIP140 prevented mitochondrial depletion and dysfunction, bioenergetic failure, inflammatory dysregulation, axonal degeneration and associated locomotor disabilities in vivo in X-ALD mouse models. Conclusions: Together, these findings show that aberrant overactivation of RIP140 promotes neurodegeneration in X-ALD, underscoring its potential as a therapeutic target for X-ALD and other neurodegenerative disorders that present with metabolic and inflammatory dyshomeostasis., This study was funded by the Institute of Health Carlos III through projects FIS PI14/01115 and FIS PI17/00134 to M.P.O., FIS PI13/00584 and FIS PI14/00328 to R.P., FIS PI19/0108 to S.F., and FIS PI14/00410, FIS PI17/00916, and FIS PI20/00759 to A.P. and was co-funded by the European Regional Development Fund (ERDF, a way to build Europe). This study was funded by the Institute of Health Carlos III through grants PFIS FI12/00457 to P.R-R. and Miguel Servet program CPII16/00016 to S.F. and co-funded by the European Social Fund (ESF, investing in your future). This study was supported by the European Commission (FP7-241622 to A.P.); the Autonomous Government of Catalonia (2014SGR168 to R.P. and 2017SGR1206 to A.P.); and the Center for Biomedical Research on Rare Diseases (CIBERER), an initiative of the Institute of Health Carlos III (M.R.). Locomotor experiments were performed by the SEFALer unit F5 led by A.P., which belongs to the CIBERER structure. We thank the CERCA Program/Generalitat de Catalunya for institutional support.
Repositori Obert UdL
Publication Artículo científico (JournalArticle)

Oxidative damage compromises energy metabolism in the axonal degeneration mouse model of X-Adrenoleukodystrophy

  • Fourcade, Stéphane
  • Schlüter, Agatha
  • López Erauskin, Jone
  • Guilera, Cristina
  • Jové Font, Mariona
  • Naudí i Farré, Alba
  • García Arumí, Elena
  • Andreu, Antoni L.
  • Starkov, Anatoly A.
  • Pamplona Gras, Reinald
  • Ferrer, Isidre
  • Portero Otín, Manuel
  • Pujol, Aurora
Aims: Chronic metabolic impairment and oxidative stress are associated with the pathogenesis of axonal dysfunction in a growing number of neurodegenerative conditions. To investigate the intertwining of both noxious factors, we have chosen the mouse model of adrenoleukodystrophy (X-ALD), which exhibits axonal degeneration in spinal cords and motor disability. The disease is caused by loss of function of the ABCD1 transporter, involved in the import and degradation of very long-chain fatty acids (VLCFA) in peroxisomes. Oxidative stress due to VLCFA excess appears early in the neurodegenerative cascade. Results: In this study, we demonstrate by redox proteomics that oxidative damage to proteins specifically affects five key enzymes of glycolysis and TCA (Tricarboxylic acid) cycle in spinal cords of Abcd1− mice and pyruvate kinase in human X-ALD fibroblasts. We also show that NADH and ATP levels are significantly diminished in these samples, together with decrease of pyruvate kinase activities and GSH levels, and increase of NADPH. Innovation: Treating Abcd1− mice with the antioxidants N-acetylcysteine and α-lipoic acid (LA) prevents protein oxidation; preserves NADH, NADPH, ATP, and GSH levels; and normalizes pyruvate kinase activity, which implies that oxidative stress provoked by VLCFA results in bioenergetic dysfunction, at a presymptomatic stage. Conclusion: Our results provide mechanistic insight into the beneficial effects of antioxidants and enhance the rationale for translation into clinical trials for X-adrenoleukodystrophy. Antioxid. Redox Signal. 15, 2095–2107., This study was supported by grants from the European Commission [FP7-241622], the European Leukodystrophy Association [ELA2009-036C5; ELA2008-040C4], the Spanish Institute for Health Carlos III [FIS PI080991 and FIS PI051118], and the Autonomous Government of Catalonia [2009SGR85] to A.P. The CIBER de Enfermedades Raras is an initiative of the ISCIII. The study was developed under the COST action BM0604 [to A.P.]. J. L-E. was a fellow of the Department of Education, Universities, and Research of the Basque Regional Government [BFI07.126]. S.F. was a fellow of the European Leukodystrophy Association [ELA 2007-018F4], and J.G. was a fellow of the IDIBELL program of PhD-student fellowships. Work carried out at the Department of Experimental Medicine was supported in part by R+D grants from the Spanish Ministry of Science and Innovation [AGL2006-12433 and BFU2009-11879/BFI], the Spanish Ministry of Health [RD06/0013/0012 and PI081843], the Autonomous Government of Catalonia [2009SGR735], and COST B35 Action of the European Union. The authors are indebted to Professor Isabel Fabregat for scientific discussion.
Repositori Obert UdL
Publication Artículo científico (JournalArticle)

Biomarker Identification, Safety, and Efficacy of High-Dose Antioxidants for Adrenomyeloneuropathy: a Phase II Pilot Study

  • Casasnovas, Carlos
  • Ruiz, Montserrat
  • Schlüter, Agatha
  • Naudí i Farré, Alba
  • Fourcade, Stéphane
  • Veciana, Misericordia
  • Castañer, Sara
  • Albertí, Antonia
  • Bargalló, Nuria
  • Johnson, Maria
  • Raymond, Gerald V.
  • Fatemi, Ali
  • Moser, Ann B.
  • Villarroya, Francesc
  • Portero Otín, Manuel
  • Artuch, Rafael
  • Pamplona Gras, Reinald
  • Pujol, Aurora
X-Adrenoleukodystrophy (X-ALD) and its adult-onset, most prevalent variant adrenomyeloneuropathy (AMN) are caused by mutations in the peroxisomal transporter of the very long-chain fatty acid ABCD1. AMN patients classically present spastic paraparesis that can progress over decades, and a satisfactory treatment is currently lacking. Oxidative stress is an early culprit in X-ALD pathogenesis. A combination of antioxidants halts the clinical progression and axonal damage in a murine model of AMN, providing a strong rationale for clinical translation. In this phase II pilot, open-label study, 13 subjects with AMN were administered a high dose of α-tocopherol, N-acetylcysteine, and α-lipoic acid in combination. The primary outcome was the validation of a set of biomarkers for monitoring the biological effects of this and future treatments. Functional clinical scales, the 6-minute walk test (6MWT), electrophysiological studies, and cerebral MRI served as secondary outcomes. Most biomarkers of oxidative damage and inflammation were normalized upon treatment, indicating an interlinked redox and inflammatory homeostasis. Two of the inflammatory markers, MCP1 and 15-HETE, were predictive of the response to treatment. We also observed a significant decrease in central motor conduction time, together with an improvement or stabilization of the 6MWT in 8/10 subjects. This study provides a series of biomarkers that are useful to monitor redox and pro-inflammatory target engagement in future trials, together with candidate biomarkers that may serve for patient stratification and disease progression, which merit replication in future clinical trials. Moreover, the clinical results suggest a positive signal for extending these studies to phase III randomized, placebo-controlled, longer-term trials with the actual identified dose. ClinicalTrials.gov Identifier: NCT01495260., This study was funded by grants from the Spanish Ministry of Health, Social Services and Equality (EC10-137), the Spanish Institute Health Carlos III (ICI14/0076) (co-funded by European Regional Development Fund, a way to build Europe), the Hesperia Foundation, the European Commission (Leukotreat FP7-241622), and the Autonomous Government of Catalonia (2014SGR1430; 2017SGR1206) to Aurora Pujol. Montserrat Ruiz was funded by the Center for Biomedical Research on Rare Diseases, an initiative of the Institute of Health Carlos III. Stéphane Fourcade was funded by Miguel Servet Program (CPII16/00016) (co-funded by European Social Fund, investing in your future). Alba Naudí, Manuel Portero-Otín, and Reinald Pamplona have received funding support from the Spanish Ministry of Science and Innovation (BFU2009-11879/BFI).
Repositori Obert UdL
Publication Artículo científico (JournalArticle)

Oxidative stress underlying axonal degeneration in adrenoleukodystrophy: a paradigm for multifactorial neurodegenerative diseases?

  • Galea, Elena
  • Launay, Nathalie
  • Portero Otín, Manuel
  • Ruiz, Montserrat
  • Pamplona Gras, Reinald
  • Aubourg, Patrick
  • Ferrer, Isidre
  • Pujol, Aurora
X-linked adrenoleukodystrophy (X-ALD) is an inherited neurodegenerative disorder expressed as four disease variants characterized by adrenal insufficiency and graded damage in the nervous system. X-ALD is caused by a loss of function of the peroxisomal ABCD1 fatty-acid transporter, resulting in the accumulation of very long chain fatty acids (VLCFA) in the organs and plasma, which have potentially toxic effects in CNS and adrenal glands. We have recently shown that treatment with a combination of antioxidants containing α-tocopherol, N-acetyl-cysteine and α-lipoic acid reversed oxidative damage and energetic failure, together with the axonal degeneration and locomotor impairment displayed by Abcd1 null mice, the animal model of X-ALD. This is the first direct demonstration that oxidative stress, which is a hallmark not only of X-ALD, but also of other neurodegenerative processes, such as Alzheimer's disease (AD), Parkinson's disease (PD) and Huntington's disease (HD), contributes to axonal damage. The purpose of this review is, first, to discuss the molecular and cellular underpinnings of VLCFA-induced oxidative stress, and how it interacts with energy metabolism and/or inflammation to generate a complex syndrome wherein multiple factors are contributing. Particular attention will be paid to the dysregulation of redox homeostasis by the interplay between peroxisomes and mitochondria. Second, we will extend this analysis to the aforementioned neurodegenerative diseases with the aim of defining differences as well as the existence of a core pathogenic mechanism that would justify the exchange of therapeutic opportunities among these pathologies. This article is part of a Special Issue entitled: Metabolic functions and biogenesis of peroxisomes in health and disease., The work of the authors of this review was supported by grants from the European Commission (FP7-241622), the European Leukodystrophy Association (ELA2009-041D6; ELA2008-040C4), the Oliver's Army, the Spanish Institute for Health Carlos III (FIS PI080991), and the Autonomous Government of Catalonia (2009SGR85) to A.P. Centro de Investigación en Red sobre Enfermedades Raras (CIBERER) is an initiative of the Instituto de Salud Carlos III. The study was developed under the COST action BM0604 (to A.P.). Work carried out at the Department of Experimental Medicine was supported in part by R+D grants from the Spanish Ministry of Science and Innovation [BFU2009-11879/BFI], the Spanish Ministry of Health [PI081843, PI0111532], the Autonomous Government of Catalonia [2009SGR735], ‘La Caixa’ Foundation, and COST B35 Action of the European Union to M.P.O. and R.P.
Repositori Obert UdL
Publication Artículo científico (JournalArticle)

Activation of sirtuin 1 as therapy for the peroxisomal disease adrenoleukodystrophy

  • Morató, Laia
  • Ruiz, M.
  • Boada Pallàs, Jordi
  • Calingasan, Noel Ylagan
  • Galino, Jorge
  • Guilera, Cristina
  • Jové Font, Mariona
  • Naudí i Farré, Alba
  • Ferrer, Isidre
  • Pamplona Gras, Reinald
  • Serrano, M.
  • Portero Otín, Manuel
  • Beal, M. F.
  • Fourcade, Stéphane
  • Pujol, Aurora
Oxidative stress and mitochondrial failure are prominent factors in the axonal degeneration process. In this study, we demonstrate that sirtuin 1 (SIRT1), a key regulator of the mitochondrial function, is impaired in the axonopathy and peroxisomal disease X-linked adrenoleukodystrophy (X-ALD). We have restored SIRT1 activity using a dual strategy of resveratrol treatment or by the moderate transgenic overexpression of SIRT1 in a X-ALD mouse model. Both strategies normalized redox homeostasis, mitochondrial respiration, bioenergetic failure, axonal degeneration and associated locomotor disabilities in the X-ALD mice. These results indicate that the reactivation of SIRT1 may be a valuable strategy to treat X-ALD and other axonopathies in which the control of redox and energetic homeostasis is impaired., This work was supported by grants from the European Commission [FP7-241622], the Spanish Institute for Health Carlos III [FIS PI11/01043], the Oliver’s Army Foundation, the Government of Catalonia [2009SGR85 to AP], the Spanish Institute for Health Carlos III [Miguel Servet program CP11/00080 to S.F.], the European Leukodystrophy Association (ELA) [ELA 2010-020F1 to SF, ELA 2013-003F1 to LM], the Spanish Ministry of Education [FPU program AP2008-03728 to LM]. JG held an IDIBELL PhD fellowship. The studies conducted at the Experimental Medicine Department were supported in part by R+D grants from the Spanish Ministry of Science and Innovation [BFU2009-11879/BFI], the Spanish Ministry of Health [PI081843, PI1300584], the Government of Catalonia [2009SGR735], the 'La Caixa' Foundation and COST B35 Action of the European Union. CIBERER and CIBERNED are initiatives of the Spanish Institute for Health Carlos III.
Repositori Obert UdL
Publication Artículo científico (JournalArticle)

Pioglitazone halts axonal degeneration in a mouse model of X-linked adrenoleukodystrophy

  • Morató, Laia
  • Galino, Jorge
  • Ruiz, Montserrat
  • Calingasan, Noel Ylagan
  • Starkov, Anatoly A.
  • Dumont, Magali
  • Naudí i Farré, Alba
  • Martínez, Juan José
  • Aubourg, Patrick
  • Portero Otín, Manuel
  • Pamplona Gras, Reinald
  • Galea, Elena
  • Flint Beal, M.
  • Ferrer, Isidre
  • Fourcade, Stéphane
  • Pujol, Aurora
X-linked adrenoleukodystrophy is a neurometabolic disorder caused by inactivation of the peroxisomal ABCD1 transporter of very long-chain fatty acids. In mice, ABCD1 loss causes late onset axonal degeneration in the spinal cord in association with locomotor disability resembling the most common phenotype in patients, adrenomyeloneuropathy. Increasing evidence indicates that oxidative stress and bioenergetic failure play major roles in the pathogenesis of X-linked adrenoleukodystrophy. In this study, we aimed to evaluate whether mitochondrial biogenesis is affected in X-linked adrenoleukodystrophy. We demonstrated that Abcd1 null mice show reduced mitochondrial DNA concomitant with downregulation of mitochondrial biogenesis pathway driven by PGC-1α/PPARγ and reduced expression of mitochondrial proteins cytochrome c, NDUFB8 and VDAC. Moreover, we show that the oral administration of pioglitazone, an agonist of PPARγ, restored mitochondrial content and expression of master regulators of biogenesis, neutralized oxidative damage to proteins and DNA, and reversed bioenergetic failure in terms of ATP levels, NAD+/NADH ratios, pyruvate kinase and glutathione reductase activities. Most importantly, the treatment halted locomotor disability and axonal damage in X-linked adrenoleukodystrophy mice. These results lend support to the use of pioglitazone in clinical trials with patients with adrenomyeloneuropathy and reveal novel molecular mechanisms of action of pioglitazone in neurodegeneration. Future studies should address the effects of this anti-diabetic drug on other axonopathies in which oxidative stress and mitochondrial dysfunction are contributing factors., This work was supported by grants from the European Commission [FP7-241622], the European Leukodystrophy Association [ELA2009-036C5, ELA2008-040C4], the Spanish Institute for Health Carlos III [FIS PI11/01043], the Autonomous Government of Catalonia [2009SGR85 to A.P.], the Spanish Institute for Health Carlos III [Miguel Servet program CP11/ 00080 to S.F.], the COST action [BM0604 to A.P.]. S.F. was a fellow of the European Leukodystrophy Association [ELA 2010- 020F1]. L.M. is a fellow of the Spanish Ministry of Education [FPU program: AP2008-03728]. J.G. was a fellow of IDIBELL. The studies conducted at the Experimental Medicine Department were supported in part by R +D grants from the Spanish Ministry of Science and Innovation [BFU2009-11879/BFI], the Spanish Ministry of Health [PI081843], the Autonomous Government of Catalonia [2009SGR735], the ‘La Caixa’ Foundation and COST B35 Action of the European Union. The CIBER on Rare Diseases (CIBERER) and the CIBER on Neurodegenerative Diseases (CIBERNED) are initiatives of the ISCIII.
Repositori Obert UdL
Publication Artículo científico (JournalArticle)

Aberrant regulation of the GSK-3b/NRF2 axis unveils a novel therapy for adrenoleukodystrophy

  • Ranea-Robles, Pablo
  • Launay, Nathalie
  • Ruiz, Montserrat
  • Calingasan, Noel Ylagan
  • Dumont, Magali
  • Naudí i Farré, Alba
  • Portero Otín, Manuel
  • Pamplona Gras, Reinald
  • Ferrer, Isidre
  • Beal, M. Flint
  • Fourcade, Stéphane
  • Pujol, Aurora
The nuclear factor erythroid 2-like 2 (NRF2) is the master regulator of endogenous antioxidant responses. Oxidative damage is a shared and early-appearing feature in X-linked adrenoleukodystrophy (X-ALD) patients and the mouse model (Abcd1 null mouse). This rare neurometabolic disease is caused by the loss of function of the peroxisomal transporter ABCD1, leading to an accumulation of very long-chain fatty acids and the induction of reactive oxygen species of mitochondrial origin. Here, we identify an impaired NRF2 response caused by aberrant activity of GSK-3b. We find that GSK-3b inhibitors can significantly reactivate the blunted NRF2 response in patients’ fibroblasts. In the mouse models (Abcd1 and Abcd1 /Abcd2 / mice), oral administration of dimethyl fumarate (DMF/BG12/Tecfidera), an NRF2 activator in use for multiple sclerosis, normalized (i) mitochondrial depletion, (ii) bioenergetic failure, (iii) oxidative damage, and (iv) inflammation, highlighting an intricate cross-talk governing energetic and redox homeostasis in XALD. Importantly, DMF halted axonal degeneration and locomotor disability suggesting that therapies activating NRF2 hold therapeutic potential for X-ALD and other axonopathies with impaired GSK- 3b/NRF2 axis., This study was supported by grants from the Spanish Institute for Health Carlos III and “Fondo Europeo de Desarrollo Regional (FEDER), Union Europea, una manera de hacer Europa” [PFIS FI12/00457] to P.R-R., [FIS PI14/ 01115, FIS PI17/00134] to M.P.O., [FIS PI13/00584, FIS PI14/00328] to R.P., [FIS PI11/01043, FIS PI14/00410, FIS PI17/00916] to A.P., [Miguel Servet program CP11/00080, CPII16/00016, FIS PI15/00857] to S.F.; the European Commission [FP7-241622] to A.P., the European Leukodystrophy Association [ELA2012-033C1] to A.P; the Autonomous Government of Catalonia [SGR 2017SGR696] to R.P. and [SGR 2014SGR1430; 2017SGR1206] to A.P.; and the Centre for Biomedical Research on Rare Diseases (CIBERER) to N.L. and M.R. Locomotor experiments were performed by the SEFALer unit F5 (CIBERER) led by A.P.
Repositori Obert UdL
Publication Artículo científico (JournalArticle)

Altered glycolipid and glycerophospholipid signaling drive inflammatory cascades in adrenomyeloneuropathy

  • Ruiz, Montserrat
  • Jové Font, Mariona
  • Schlüter, Agatha
  • Casasnovas, Carlos
  • Villarroya, Francesc
  • Guilera, Cristina
  • Ortega, Francisco J.
  • Naudí i Farré, Alba
  • Pamplona Gras, Reinald
  • Gimeno, Ramón
  • Fourcade, Stéphane
  • Portero Otín, Manuel
  • Pujol, Aurora
X-linked adrenomyeloneuropathy (AMN) is an inherited neurometabolic disorder caused by malfunction of the ABCD1 gene, characterized by slowly progressing spastic paraplegia affecting corticospinal tracts, and adrenal insufficiency. AMN is the most common phenotypic manifestation of adrenoleukodystrophy (X-ALD). In some cases, an inflammatory cerebral demyelination occurs associated to poor prognosis in cerebral AMN (cAMN). Though ABCD1 codes for a peroxisomal transporter of very long-chain fatty acids, the molecular mechanisms that govern disease onset and progression, or its transformation to a cerebral, inflammatory demyelinating form, remain largely unknown. Here we used an integrated -omics approach to identify novel biomarkers and altered network dynamic characteristic of, and possibly driving, the disease. We combined an untargeted metabolome assay of plasma and peripheral blood mononuclear cells (PBMC) of AMN patients, which used liquid chromatography coupled to quadrupole-time-of-flight mass spectrometry (LC-Q-TOF), with a functional genomics analysis of spinal cords of Abcd1− mouse. The results uncovered altered nodes in lipid-driven proinflammatory cascades, such as glycosphingolipid and glycerophospholipid synthesis, governed by the β-1,4-galactosyltransferase (B4GALT6), the phospholipase 2γ (PLA2G4C) and the choline/ethanolamine phosphotransferase (CEPT1) enzymes. Confirmatory investigations revealed a non-classic, inflammatory profile, consisting on the one hand of raised plasma levels of several eicosanoids derived from arachidonic acid through PLA2G4C activity, together with also the proinflammatory cytokines IL6, IL8, MCP-1 and tumor necrosis factor-α. In contrast, we detected a more protective, Th2-shifted response in PBMC. Thus, our findings illustrate a previously unreported connection between ABCD1 dysfunction, glyco- and glycerolipid-driven inflammatory signaling and a fine-tuned inflammatory response underlying a disease considered non-inflammatory., We are indebted to Dr Arndt G. Benecke for critically reading the manuscript. This study was supported by grants from the Hesperia Foundation, the Asociación Española contra las Leucodistrofias (ALE-ELA España), the Spanish Ministry for Health and Social Policy (MSPSI EC10-137), the European Commission (FP7- 241622), the Spanish Institute for Health Carlos III and ‘Fondo Europeo de Desarrollo Regional (FEDER), Unión Europea, una manera de hacer Europa’ (FIS PI11/01043, FIS PI14/00410, FIS ICI14/00076), and the Autonomous Government of Catalonia AGAUR (2009SGR85, 2014SGR1430 to A.P.); the Spanish Institute for Health Carlos III and ‘Fondo Europeo de Desarrollo Regional (FEDER), Unión Europea, una manera de hacer Europa’ (FIS PI14/ 00581) to C.C. and the Spanish Institute for Health Carlos III Miguel Servet program CP11/00080 to S.F. The studies conducted at the Department of Experimental Medicine were supported in part by R+D grants from the Spanish Ministry of Science and Innovation (BFU2009-11879/BFI), the Spanish Ministry of Health (PI111543; PI1300584, PI140115), the Autonomous Government of Catalonia (2009SGR735), the ‘La Caixa’ Foundation, and COST B35 The CIBER on Rare Diseases (CIBERER) and on Physiopathology of Obesity and Nutrition (CIBEROBN) are initiatives of the ISCIII.
Repositori Obert UdL
Publication Artículo científico (JournalArticle)

Valproic acid induces antioxidant effects in X-linked adrenoleukodystrophy

  • Fourcade, Stéphane
  • Ruiz, Montserrat
  • Guilera, Cristina
  • Hahnen, Eric
  • Brichta, Lars
  • Naudí i Farré, Alba
  • Portero Otín, Manuel
  • Dacremont, Georges
  • Cartier, Nathalie
  • Wanders, Ronald
  • Kemp, Stephan
  • Mandel, Jean Louis
  • Wirth, Brunhilde
  • Pamplona Gras, Reinald
  • Aubourg, Patrick
  • Pujol, Aurora
X-linked adrenoleukodystrophy (X-ALD) is a fatal, axonal demyelinating, neurometabolic disease. It results from the functional loss of a member of the peroxisomal ATP-binding cassette transporter subfamily D (ABCD1), which is involved in the metabolism of very long-chain fatty acids (VLCFA). Oxidative damage of proteins caused by excess of the hexacosanoic acid, the most prevalent VLCFA accumulating in X-ALD, is an early event in the neurodegenerative cascade. We demonstrate here that valproic acid (VPA), a widely used anti-epileptic drug with histone deacetylase inhibitor properties, induced the expression of the functionally overlapping ABCD2 peroxisomal transporter. VPA corrected the oxidative damage and decreased the levels of monounsaturated VLCFA (C26:1 n-9), but not saturated VLCFA. Overexpression of ABCD2 alone prevented oxidative lesions to proteins in a mouse model of X-ALD. A 6-month pilot trial of VPA in X-ALD patients resulted in reversion of the oxidative damage of proteins in peripheral blood mononuclear cells. Thus, we propose VPA as a promising novel therapeutic approach that warrants further clinical investigation in X-ALD., This work was supported by grants from the European Commission (LSHM-CT2004-502987 and FP7-241622), the European Leukodystrophy Association (ELA 2006-043I4), the Spanish Institute for Health Carlos III (FIS PI080991 and FIS PI051118) and the Autonomous Government of Catalonia (2009SGR85) to A.P. S.F. was a fellow of the European Leukodystrophy Association (ELA 2007-018F4). S.K. also received a grant from the European Leukodystrophy Association (ELA 2006-031I4). The work was developed under the COST action BM0604 (to A.P.). The CIBER de Enfermedades Raras is an initiative of the ISCIII. Work carried out at the Department of Experimental Medicine was supported in part by I + D grants from the Spanish Ministry of Science and Innovation (AGL2006-12433 and BFU2009-11879/BFI), the Spanish Ministry of Health (RD06/0013/0012 and PI081843), the Autonomous Government of Catalonia (2009SGR735), ‘La Caixa’ Foundation and COST B35 Action from the European Union. A.N. received a predoctoral fellowship from ‘La Caixa’ Foundation.
Repositori Obert UdL
Publication Artículo científico (JournalArticle)

Impaired mitochondrial oxidative phosphorylation in the peroxisomal disease X-linked adrenoleukodystrophy

  • López Erauskin, Jone
  • Galino, Jorge
  • Ruiz, M.
  • Cuezva, J. M.
  • Fabregat, I.
  • Cacabelos Barral, Daniel
  • Boada Pallàs, Jordi
  • Martínez, Juan José
  • Ferrer, Isidre
  • Pamplona Gras, Reinald
  • Villarroya, Francesc
  • Portero Otín, Manuel
  • Fourcade, Stéphane
  • Pujol, Aurora
X-linked adrenoleukodystrophy (X-ALD) is an inherited metabolic disorder of the nervous system characterized by axonopathy in spinal cords and/or cerebral demyelination, adrenal insufficiency and accumulation of very long-chain fatty acids (VLCFAs) in plasma and tissues. The disease is caused by malfunction of the ABCD1 gene, which encodes a peroxisomal transporter of VLCFAs or VLCFA-CoA. In the mouse, Abcd1 loss causes late onset axonal degeneration in the spinal cord, associated with locomotor disability resembling the most common phenotype in patients, adrenomyeloneuropathy. We have formerly shown that an excess of the VLCFA C26:0 induces oxidative damage, which underlies the axonal degeneration exhibited by the Abcd1− mice. In the present study, we sought to investigate the noxious effects of C26:0 on mitochondria function. Our data indicate that in X-ALD patients' fibroblasts, excess of C26:0 generates mtDNA oxidation and specifically impairs oxidative phosphorylation (OXPHOS) triggering mitochondrial ROS production from electron transport chain complexes. This correlates with impaired complex V phosphorylative activity, as visualized by high-resolution respirometry on spinal cord slices of Abcd1− mice. Further, we identified a marked oxidation of key OXPHOS system subunits in Abcd1− mouse spinal cords at presymptomatic stages. Altogether, our results illustrate some of the mechanistic intricacies by which the excess of a fatty acid targeted to peroxisomes activates a deleterious process of oxidative damage to mitochondria, leading to a multifaceted dysfunction of this organelle. These findings may be of relevance for patient management while unveiling novel therapeutic targets for X-ALD., This study was supported by grants from the European Commission (FP7-241622), the European Leukodystrophy Association (ELA2009-036C5; ELA2008-040C4), the Spanish Institute for Health Carlos III (FIS PI080991 and FIS PI11/01043), the Autonomous Government of Catalonia (2009SGR85) to A.P. and the Spanish Institute for Health Carlos III (Miguel Servet program CP11/00080) to S.F. The CIBER on Rare Diseases (CIBERER) is an initiative of the ISCIII. The study was developed under the COST action BM0604 (to A.P.). J.L.-E. was a fellow of the Department of Education, Universities and Research of the Basque Country Government (BFI07.126). S.F. was a fellow of the European Leukodystrophy Association (ELA 2010-020F1). The studies conducted at the Department of Experimental Medicine were supported in part by R&D grants from the Spanish Ministry of Science and Innovation (BFU2009-11879/BFI), the Spanish Ministry of Health (PI11/ 1532), the Autonomous Government of Catalonia (2009SGR735), the ‘La Caixa’ Foundation and COST B35 Action of the European Union. D.C. is a fellow from the Spanish Ministry of Health (FI08-00707). The studies conducted at the Department of Biochemistry and Molecular Biology, University of Barcelona, were supported by grants SAF2008-01896 and SAF2011-23636 from the Spanish Ministry of Science and Innovation. The CIBER in Physiopathology of Obesity and Nutrition (CIBERobn) is an initiative of the ISCIII.
Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

Oxidative damage compromises energy metabolism in the axonal degeneration mouse model of X-adrenoleukodystrophy

  • Galino, Jorge
  • Ruiz, Montserrat
  • Fourcade, Stéphane
  • Schlüter, Agatha
  • López Erauskin, Jone
  • Guilera, Cristina
  • Jove, Mariona
  • Naudi, Alba
  • García Arumí, Elena
  • Andreu, Antoni L.
  • Starkov, Anatoly A.
  • Pamplona, Reinald
  • Ferrer, Isidro (Ferrer Abizanda)
  • Portero-Otin, Manuel
  • Pujol Onofre, Aurora
Aims: Chronic metabolic impairment and oxidative stress are associated with the pathogenesis of axonal dysfunction in a growing number of neurodegenerative conditions. To investigate the intertwining of both noxious factors, we have chosen the mouse model of adrenoleukodystrophy (X-ALD), which exhibits axonal degeneration in spinal cords and motor disability. The disease is caused by loss of function of the ABCD1 transporter, involved in the import and degradation of very long-chain fatty acids (VLCFA) in peroxisomes. Oxidative stress due to VLCFA excess appears early in the neurodegenerative cascade. Results: In this study, we demonstrate by redox proteomics that oxidative damage to proteins specifically affects five key enzymes of glycolysis and TCA (Tricarboxylic acid) cycle in spinal cords of Abcd1(-) mice and pyruvate kinase in human X-ALD fibroblasts. We also show that NADH and ATP levels are significantly diminished in these samples, together with decrease of pyruvate kinase activities and GSH levels, and increase of NADPH. Innovation: Treating Abcd1(-) mice with the antioxidants N-acetylcysteine and alpha-lipoic acid (LA) prevents protein oxidation; preserves NADH, NADPH, ATP, and GSH levels; and normalizes pyruvate kinase activity, which implies that oxidative stress provoked by VLCFA results in bioenergetic dysfunction, at a presymptomatic stage. Conclusion: Our results provide mechanistic insight into the beneficial effects of antioxidants and enhance the rationale for translation into clinical trials for X-adrenoleukodystrophy. Antioxid. Redox Signal. 15, 2095-2107.
Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

Autophagy induction halts axonal degeneration in a mouse model of x-adrenoleukodystrophy

  • Launay, Nathalie
  • Aguado, Carmen
  • Fourcade, Stéphane
  • Ruiz, Montserrat
  • Grau, Laia
  • Riera, Jordi
  • Guilera, Cristina
  • Giròs, Marisa
  • Ferrer, Isidro (Ferrer Abizanda)
  • Knecht, Erwin
  • Pujol Onofre, Aurora
X-linked adrenoleukodystrophy (X-ALD) is a rare neurometabolic disease characterized by the accumulation of very long chain fatty acids (VLCFAs) due to a loss of function of the peroxisomal transporter ABCD1. Here, using in vivo and in vitro models, we demonstrate that autophagic flux was impaired due to elevated mammalian target of rapamycin (mTOR) signaling, which contributed to X-ALD pathogenesis. We also show that excess VLCFAs downregulated autophagy in human fibroblasts. Furthermore, mTOR inhibition by a rapamycin derivative (temsirolimus) restored autophagic flux and inhibited the axonal degenerative process as well as the associated locomotor impairment in the Abcd1 (-) /Abcd2 (-/-) mouse model. This process was mediated through the restoration of proteasome function and redox as well as metabolic homeostasis. These findings provide the first evidence that links impaired autophagy to X-ALD, which may yield a therapy based on autophagy activators for adrenomyeloneuropathy patients.
Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

Tauroursodeoxycholic bile acid arrests axonal degeneration by inhibiting the unfolded protein response in X-linked adrenoleukodystrophy

  • Launay, Nathalie
  • Ruiz, Montserrat
  • Grau, Laia
  • Ortega González, Fco. Javier
  • Ilieva, Ekaterina V.
  • Martínez, Juan José
  • Galea, Elena
  • Ferrer, Isidro (Ferrer Abizanda)
  • Knecht, Erwin
  • Pujol Onofre, Aurora
  • Fourcade, Stéphane
The activation of the highly conserved unfolded protein response (UPR) is prominent in the pathogenesis of the most prevalent neurodegenerative disorders, such as Alzheimer's disease (AD), Parkinson's disease (PD) and amyotrophic lateral sclerosis (ALS), which are classically characterized by an accumulation of aggregated or misfolded proteins. This activation is orchestrated by three endoplasmic reticulum (ER) stress sensors: PERK, ATF6 and IRE1. These sensors transduce signals that induce the expression of the UPR gene programme. Here, we first identified an early activator of the UPR and investigated the role of a chronically activated UPR in the pathogenesis of X-linked adrenoleukodystrophy (X-ALD), a neurometabolic disorder that is caused by ABCD1 malfunction; ABCD1 transports very long-chain fatty acids (VLCFA) into peroxisomes. The disease manifests as inflammatory demyelination in the brain or and/or degeneration of corticospinal tracts, thereby resulting in spastic paraplegia, with the accumulation of intracellular VLCFA instead of protein aggregates. Using X-ALD mouse model (Abcd1 - and Abcd1 - /Abcd2 -/- mice) and X-ALD patient's fibroblasts and brain samples, we discovered an early engagement of the UPR. The response was characterized by the activation of the PERK and ATF6 pathways, but not the IRE1 pathway, showing a difference from the models of AD, PD or ALS. Inhibition of PERK leads to the disruption of homeostasis and increased apoptosis during ER stress induced in X-ALD fibroblasts. Redox imbalance appears to be the mechanism that initiates ER stress in X-ALD. Most importantly, we demonstrated that the bile acid tauroursodeoxycholate (TUDCA) abolishes UPR activation, which results in improvement of axonal degeneration and its associated locomotor impairment in Abcd1 - /Abcd2 -/- mice. Altogether, our preclinical data provide evidence for establishing the UPR as a key drug target in the pathogenesis cascade. Our study also highlights the potential role of TUDCA as a treatment for X-ALD and other axonopathies in which similar molecular mediators are implicated.
Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

Aberrant regulation of the GSK-3β/NRF2 axis unveils a novel therapy for adrenoleukodystrophy

  • Ranea Robles, Pablo
  • Launay, Nathalie
  • Ruiz, Montserrat
  • Calingasan, Noel Ylagan
  • Dumont, Magali
  • Naudi, Alba
  • Portero-Otin, Manuel
  • Pamplona, Reinald
  • Ferrer, Isidro (Ferrer Abizanda)
  • Beal, M. Flint
  • Fourcade, Stéphane
  • Pujol Onofre, Aurora
The nuclear factor erythroid 2‐like 2 (NRF2) is the master regulator of endogenous antioxidant responses. Oxidative damage is a shared and early‐appearing feature in X‐linked adrenoleukodystrophy (X‐ALD) patients and the mouse model (Abcd1 null mouse). This rare neurometabolic disease is caused by the loss of function of the peroxisomal transporter ABCD1, leading to an accumulation of very long‐chain fatty acids and the induction of reactive oxygen species of mitochondrial origin. Here, we identify an impaired NRF2 response caused by aberrant activity of GSK‐3β. We find that GSK‐3β inhibitors can significantly reactivate the blunted NRF2 response in patients' fibroblasts. In the mouse models (Abcd1 − and Abcd1 −/Abcd2 −/− mice), oral administration of dimethyl fumarate (DMF/BG12/Tecfidera), an NRF2 activator in use for multiple sclerosis, normalized (i) mitochondrial depletion, (ii) bioenergetic failure, (iii) oxidative damage, and (iv) inflammation, highlighting an intricate cross‐talk governing energetic and redox homeostasis in X‐ALD. Importantly, DMF halted axonal degeneration and locomotor disability suggesting that therapies activating NRF2 hold therapeutic potential for X‐ALD and other axonopathies with impaired GSK‐3β/NRF2 axis. Keywords: adrenoleukodystrophy, dimethyl fumarate, GSK‐3, NRF2, oxidative stress Subject Categories: Genetics, Gene Therapy & Genetic Disease, Metabolism, Neuroscience
Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

Cyclophilin D as a potential target for antioxidants in neurodegeneration: the X-ALD case

  • López Erauskin, Jone
  • Ferrer, Isidro (Ferrer Abizanda)
  • Galea, Elena
  • Pujol Onofre, Aurora
Abstract: X-linked adrenoleukodystrophy (X-ALD) is a severe inherited neurodegenerative disorder characterized by adrenal insufficiency and graded damage in the nervous system. Loss of function of the peroxisomal ABCD1 fatty-acid transporter, resulting in the accumulation of very long-chain fatty acids in organs and plasma, is the genetic cause. Treatment with a combination of antioxidants halts the axonal degeneration and locomotor impairment displayed by the animal model of X-ALD, and is a proof of concept that oxidative stress contributes to axonal damage. New evidence demonstrates that metabolic failure and the opening of the mitochondrial permeability transition pore orchestrated by cyclophilin D underlies oxidative stress-induced axonal degeneration. Thus, cyclophilin D could serve as a therapeutic target for the treatment of X-ALD and cyclophilin D-dependent neurodegenerative and non-neurodegenerative diseases.
Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

Biomarker Identification, Safety, and Efficacy of High-Dose Antioxidants for Adrenomyeloneuropathy: a Phase II Pilot Study

  • Casasnovas Pons, Carlos
  • Ruiz, Montserrat
  • Schlüter, Agatha
  • Naudi, Alba
  • Fourcade, Stéphane
  • Veciana, Misericordia
  • Castañer, Sara
  • Albertí, Antonia
  • Bargalló Alabart, Núria
  • Johnson, Maria
  • Raymond, Gerald V.
  • Fatemi, Ali
  • Moser, Ann B.
  • Villarroya i Gombau, Francesc
  • Portero-Otin, Manuel
  • Artuch Iriberri, Rafael
  • Pamplona, Reinald
  • Pujol, Aurora, 1968-
X-Adrenoleukodystrophy (X-ALD) and its adult-onset, most prevalent variant adrenomyeloneuropathy (AMN) are caused by mutations in the peroxisomal transporter of the very long-chain fatty acid ABCD1. AMN patients classically present spastic paraparesis that can progress over decades, and a satisfactory treatment is currently lacking. Oxidative stress is an early culprit in X-ALD pathogenesis. A combination of antioxidants halts the clinical progression and axonal damage in a murine model of AMN, providing a strong rationale for clinical translation. In this phase II pilot, open-label study, 13 subjects with AMN were administered a high dose of α-tocopherol, N-acetylcysteine, and α-lipoic acid in combination. The primary outcome was the validation of a set of biomarkers for monitoring the biological effects of this and future treatments. Functional clinical scales, the 6-minute walk test (6MWT), electrophysiological studies, and cerebral MRI served as secondary outcomes. Most biomarkers of oxidative damage and inflammation were normalized upon treatment, indicating an interlinked redox and inflammatory homeostasis. Two of the inflammatory markers, MCP1 and 15-HETE, were predictive of the response to treatment. We also observed a significant decrease in central motor conduction time, together with an improvement or stabilization of the 6MWT in 8/10 subjects. This study provides a series of biomarkers that are useful to monitor redox and pro-inflammatory target engagement in future trials, together with candidate biomarkers that may serve for patient stratification and disease progression, which merit replication in future clinical trials. Moreover, the clinical results suggest a positive signal for extending these studies to phase III randomized, placebo-controlled, longer-term trials with the actual identified dose. ClinicalTrials.gov Identifier: NCT01495260.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Oxidative damage compromises energy metabolism in the axonal degeneration mouse model of X-adrenoleukodystrophy

  • Galino, Jorge
  • Ruiz, Montserrat
  • Fourcade, Stéphane
  • Schlüter, Agatha
  • López Erauskin, Jone
  • Guilera, Cristina
  • Jove, Mariona
  • Naudi, Alba
  • García Arumí, Elena
  • Andreu, Antoni L.
  • Starkov, Anatoly A.
  • Pamplona, Reinald
  • Ferrer, Isidro (Ferrer Abizanda)
  • Portero-Otin, Manuel
  • Pujol Onofre, Aurora
Aims: Chronic metabolic impairment and oxidative stress are associated with the pathogenesis of axonal dysfunction in a growing number of neurodegenerative conditions. To investigate the intertwining of both noxious factors, we have chosen the mouse model of adrenoleukodystrophy (X-ALD), which exhibits axonal degeneration in spinal cords and motor disability. The disease is caused by loss of function of the ABCD1 transporter, involved in the import and degradation of very long-chain fatty acids (VLCFA) in peroxisomes. Oxidative stress due to VLCFA excess appears early in the neurodegenerative cascade. Results: In this study, we demonstrate by redox proteomics that oxidative damage to proteins specifically affects five key enzymes of glycolysis and TCA (Tricarboxylic acid) cycle in spinal cords of Abcd1(-) mice and pyruvate kinase in human X-ALD fibroblasts. We also show that NADH and ATP levels are significantly diminished in these samples, together with decrease of pyruvate kinase activities and GSH levels, and increase of NADPH. Innovation: Treating Abcd1(-) mice with the antioxidants N-acetylcysteine and alpha-lipoic acid (LA) prevents protein oxidation; preserves NADH, NADPH, ATP, and GSH levels; and normalizes pyruvate kinase activity, which implies that oxidative stress provoked by VLCFA results in bioenergetic dysfunction, at a presymptomatic stage. Conclusion: Our results provide mechanistic insight into the beneficial effects of antioxidants and enhance the rationale for translation into clinical trials for X-adrenoleukodystrophy. Antioxid. Redox Signal. 15, 2095-2107.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Aberrant regulation of the GSK-3β/NRF2 axis unveils a novel therapy for adrenoleukodystrophy

  • Ranea Robles, Pablo
  • Launay, Nathalie
  • Ruiz, Montserrat
  • Calingasan, Noel Ylagan
  • Dumont, Magali
  • Naudi, Alba
  • Portero-Otin, Manuel
  • Pamplona, Reinald
  • Ferrer, Isidro (Ferrer Abizanda)
  • Beal, M. Flint
  • Fourcade, Stéphane
  • Pujol Onofre, Aurora
The nuclear factor erythroid 2‐like 2 (NRF2) is the master regulator of endogenous antioxidant responses. Oxidative damage is a shared and early‐appearing feature in X‐linked adrenoleukodystrophy (X‐ALD) patients and the mouse model (Abcd1 null mouse). This rare neurometabolic disease is caused by the loss of function of the peroxisomal transporter ABCD1, leading to an accumulation of very long‐chain fatty acids and the induction of reactive oxygen species of mitochondrial origin. Here, we identify an impaired NRF2 response caused by aberrant activity of GSK‐3β. We find that GSK‐3β inhibitors can significantly reactivate the blunted NRF2 response in patients' fibroblasts. In the mouse models (Abcd1 − and Abcd1 −/Abcd2 −/− mice), oral administration of dimethyl fumarate (DMF/BG12/Tecfidera), an NRF2 activator in use for multiple sclerosis, normalized (i) mitochondrial depletion, (ii) bioenergetic failure, (iii) oxidative damage, and (iv) inflammation, highlighting an intricate cross‐talk governing energetic and redox homeostasis in X‐ALD. Importantly, DMF halted axonal degeneration and locomotor disability suggesting that therapies activating NRF2 hold therapeutic potential for X‐ALD and other axonopathies with impaired GSK‐3β/NRF2 axis. Keywords: adrenoleukodystrophy, dimethyl fumarate, GSK‐3, NRF2, oxidative stress Subject Categories: Genetics, Gene Therapy & Genetic Disease, Metabolism, Neuroscience
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Modulation of mitochondrial and inflammatory homeostasis through RIP140 is neuroprotective in an adrenoleukodystrophy mouse model

  • Ranea-Robles, Pablo
  • Galino, Jorge
  • Espinosa Blay, Lluís
  • Schlüter, Agatha
  • Ruiz, Montserrat
  • Calingasan, Noel Ylagan
  • Villarroya, Francesc
  • Naudí, Alba
  • Pamplona, Reinald
  • Ferrer, Isidre
  • Beal, M. Flint
  • Portero Otín, Manuel
  • Fourcade, Stéphane
  • Pujol, Aurora, 1968-
Aims: Mitochondrial dysfunction and inflammation are at the core of axonal degeneration in several multifactorial neurodegenerative diseases, including multiple sclerosis, Alzheimer's disease, and Parkinson's disease. The transcriptional coregulator RIP140/NRIP1 (receptor-interacting protein 140) modulates these functions in liver and adipose tissue, but its role in the nervous system remains unexplored. Here, we investigated the impact of RIP140 in the Abcd1- mouse model of X-linked adrenoleukodystrophy (X-ALD), a genetic model of chronic axonopathy involving the convergence of redox imbalance, bioenergetic failure, and chronic inflammation. Methods and results: We provide evidence that RIP140 is modulated through a redox-dependent mechanism driven by very long-chain fatty acids (VLCFAs), the levels of which are increased in X-ALD. Genetic inactivation of RIP140 prevented mitochondrial depletion and dysfunction, bioenergetic failure, inflammatory dysregulation, axonal degeneration and associated locomotor disabilities in vivo in X-ALD mouse models. Conclusions: Together, these findings show that aberrant overactivation of RIP140 promotes neurodegeneration in X-ALD, underscoring its potential as a therapeutic target for X-ALD and other neurodegenerative disorders that present with metabolic and inflammatory dyshomeostasis., This study was funded by the Institute of Health Carlos III through projects FIS PI14/01115 and FIS PI17/00134 to M.P.O., FIS PI13/00584 and FIS PI14/00328 to R.P., FIS PI19/0108 to S.F., and FIS PI14/00410, FIS PI17/00916, and FIS PI20/00759 to A.P. and was co-funded by the European Regional Development Fund (ERDF, a way to build Europe). This study was funded by the Institute of Health Carlos III through grants PFIS FI12/00457 to P.R-R. and Miguel Servet program CPII16/00016 to S.F. and co-funded by the European Social Fund (ESF, investing in your future). This study was supported by the European Commission (FP7-241622 to A.P.); the Autonomous Government of Catalonia (2014SGR168 to R.P. and 2017SGR1206 to A.P.); and the Center for Biomedical Research on Rare Diseases (CIBERER), an initiative of the Institute of Health Carlos III (M.R.). Locomotor experiments were performed by the SEFALer unit F5 led by A.P., which belongs to the CIBERER structure. We thank the CERCA Program/Generalitat de Catalunya for institutional support.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Tauroursodeoxycholic bile acid arrests axonal degeneration by inhibiting the unfolded protein response in X-linked adrenoleukodystrophy

  • Launay, Nathalie
  • Ruiz, Montserrat
  • Grau, Laia
  • Ortega González, Fco. Javier
  • Ilieva, Ekaterina V.
  • Martínez, Juan José
  • Galea, Elena
  • Ferrer, Isidro (Ferrer Abizanda)
  • Knecht, Erwin
  • Pujol Onofre, Aurora
  • Fourcade, Stéphane
The activation of the highly conserved unfolded protein response (UPR) is prominent in the pathogenesis of the most prevalent neurodegenerative disorders, such as Alzheimer's disease (AD), Parkinson's disease (PD) and amyotrophic lateral sclerosis (ALS), which are classically characterized by an accumulation of aggregated or misfolded proteins. This activation is orchestrated by three endoplasmic reticulum (ER) stress sensors: PERK, ATF6 and IRE1. These sensors transduce signals that induce the expression of the UPR gene programme. Here, we first identified an early activator of the UPR and investigated the role of a chronically activated UPR in the pathogenesis of X-linked adrenoleukodystrophy (X-ALD), a neurometabolic disorder that is caused by ABCD1 malfunction; ABCD1 transports very long-chain fatty acids (VLCFA) into peroxisomes. The disease manifests as inflammatory demyelination in the brain or and/or degeneration of corticospinal tracts, thereby resulting in spastic paraplegia, with the accumulation of intracellular VLCFA instead of protein aggregates. Using X-ALD mouse model (Abcd1 - and Abcd1 - /Abcd2 -/- mice) and X-ALD patient's fibroblasts and brain samples, we discovered an early engagement of the UPR. The response was characterized by the activation of the PERK and ATF6 pathways, but not the IRE1 pathway, showing a difference from the models of AD, PD or ALS. Inhibition of PERK leads to the disruption of homeostasis and increased apoptosis during ER stress induced in X-ALD fibroblasts. Redox imbalance appears to be the mechanism that initiates ER stress in X-ALD. Most importantly, we demonstrated that the bile acid tauroursodeoxycholate (TUDCA) abolishes UPR activation, which results in improvement of axonal degeneration and its associated locomotor impairment in Abcd1 - /Abcd2 -/- mice. Altogether, our preclinical data provide evidence for establishing the UPR as a key drug target in the pathogenesis cascade. Our study also highlights the potential role of TUDCA as a treatment for X-ALD and other axonopathies in which similar molecular mediators are implicated.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Cyclophilin D as a potential target for antioxidants in neurodegeneration: the X-ALD case

  • López Erauskin, Jone
  • Ferrer, Isidro (Ferrer Abizanda)
  • Galea, Elena
  • Pujol Onofre, Aurora
Abstract: X-linked adrenoleukodystrophy (X-ALD) is a severe inherited neurodegenerative disorder characterized by adrenal insufficiency and graded damage in the nervous system. Loss of function of the peroxisomal ABCD1 fatty-acid transporter, resulting in the accumulation of very long-chain fatty acids in organs and plasma, is the genetic cause. Treatment with a combination of antioxidants halts the axonal degeneration and locomotor impairment displayed by the animal model of X-ALD, and is a proof of concept that oxidative stress contributes to axonal damage. New evidence demonstrates that metabolic failure and the opening of the mitochondrial permeability transition pore orchestrated by cyclophilin D underlies oxidative stress-induced axonal degeneration. Thus, cyclophilin D could serve as a therapeutic target for the treatment of X-ALD and cyclophilin D-dependent neurodegenerative and non-neurodegenerative diseases.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Aberrant regulation of the GSK-3b/NRF2 axis unveils a novel therapy for adrenoleukodystrophy

  • Ranea-Robles, Pablo
  • Launay, Nathalie
  • Ruiz, Montserrat
  • Calingasan, Noel Ylagan
  • Dumont, Magali
  • Naudí i Farré, Alba
  • Portero Otín, Manuel
  • Pamplona Gras, Reinald
  • Ferrer, Isidre
  • Beal, M. Flint
  • Fourcade, Stéphane
  • Pujol, Aurora
The nuclear factor erythroid 2-like 2 (NRF2) is the master regulator of endogenous antioxidant responses. Oxidative damage is a shared and early-appearing feature in X-linked adrenoleukodystrophy (X-ALD) patients and the mouse model (Abcd1 null mouse). This rare neurometabolic disease is caused by the loss of function of the peroxisomal transporter ABCD1, leading to an accumulation of very long-chain fatty acids and the induction of reactive oxygen species of mitochondrial origin. Here, we identify an impaired NRF2 response caused by aberrant activity of GSK-3b. We find that GSK-3b inhibitors can significantly reactivate the blunted NRF2 response in patients’ fibroblasts. In the mouse models (Abcd1 and Abcd1 /Abcd2 / mice), oral administration of dimethyl fumarate (DMF/BG12/Tecfidera), an NRF2 activator in use for multiple sclerosis, normalized (i) mitochondrial depletion, (ii) bioenergetic failure, (iii) oxidative damage, and (iv) inflammation, highlighting an intricate cross-talk governing energetic and redox homeostasis in XALD. Importantly, DMF halted axonal degeneration and locomotor disability suggesting that therapies activating NRF2 hold therapeutic potential for X-ALD and other axonopathies with impaired GSK- 3b/NRF2 axis., This study was supported by grants from the Spanish Institute for Health Carlos III and “Fondo Europeo de Desarrollo Regional (FEDER), Union Europea, una manera de hacer Europa” [PFIS FI12/00457] to P.R-R., [FIS PI14/ 01115, FIS PI17/00134] to M.P.O., [FIS PI13/00584, FIS PI14/00328] to R.P., [FIS PI11/01043, FIS PI14/00410, FIS PI17/00916] to A.P., [Miguel Servet program CP11/00080, CPII16/00016, FIS PI15/00857] to S.F.; the European Commission [FP7-241622] to A.P., the European Leukodystrophy Association [ELA2012-033C1] to A.P; the Autonomous Government of Catalonia [SGR 2017SGR696] to R.P. and [SGR 2014SGR1430; 2017SGR1206] to A.P.; and the Centre for Biomedical Research on Rare Diseases (CIBERER) to N.L. and M.R. Locomotor experiments were performed by the SEFALer unit F5 (CIBERER) led by A.P.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Biomarker Identification, Safety, and Efficacy of High-Dose Antioxidants for Adrenomyeloneuropathy: a Phase II Pilot Study

  • Casasnovas, Carlos
  • Ruiz, Montserrat
  • Schlüter, Agatha
  • Naudí i Farré, Alba
  • Fourcade, Stéphane
  • Veciana, Misericordia
  • Castañer, Sara
  • Albertí, Antonia
  • Bargalló, Nuria
  • Johnson, Maria
  • Raymond, Gerald V.
  • Fatemi, Ali
  • Moser, Ann B.
  • Villarroya, Francesc
  • Portero Otín, Manuel
  • Artuch, Rafael
  • Pamplona Gras, Reinald
  • Pujol, Aurora
X-Adrenoleukodystrophy (X-ALD) and its adult-onset, most prevalent variant adrenomyeloneuropathy (AMN) are caused by mutations in the peroxisomal transporter of the very long-chain fatty acid ABCD1. AMN patients classically present spastic paraparesis that can progress over decades, and a satisfactory treatment is currently lacking. Oxidative stress is an early culprit in X-ALD pathogenesis. A combination of antioxidants halts the clinical progression and axonal damage in a murine model of AMN, providing a strong rationale for clinical translation. In this phase II pilot, open-label study, 13 subjects with AMN were administered a high dose of α-tocopherol, N-acetylcysteine, and α-lipoic acid in combination. The primary outcome was the validation of a set of biomarkers for monitoring the biological effects of this and future treatments. Functional clinical scales, the 6-minute walk test (6MWT), electrophysiological studies, and cerebral MRI served as secondary outcomes. Most biomarkers of oxidative damage and inflammation were normalized upon treatment, indicating an interlinked redox and inflammatory homeostasis. Two of the inflammatory markers, MCP1 and 15-HETE, were predictive of the response to treatment. We also observed a significant decrease in central motor conduction time, together with an improvement or stabilization of the 6MWT in 8/10 subjects. This study provides a series of biomarkers that are useful to monitor redox and pro-inflammatory target engagement in future trials, together with candidate biomarkers that may serve for patient stratification and disease progression, which merit replication in future clinical trials. Moreover, the clinical results suggest a positive signal for extending these studies to phase III randomized, placebo-controlled, longer-term trials with the actual identified dose. ClinicalTrials.gov Identifier: NCT01495260., This study was funded by grants from the Spanish Ministry of Health, Social Services and Equality (EC10-137), the Spanish Institute Health Carlos III (ICI14/0076) (co-funded by European Regional Development Fund, a way to build Europe), the Hesperia Foundation, the European Commission (Leukotreat FP7-241622), and the Autonomous Government of Catalonia (2014SGR1430; 2017SGR1206) to Aurora Pujol. Montserrat Ruiz was funded by the Center for Biomedical Research on Rare Diseases, an initiative of the Institute of Health Carlos III. Stéphane Fourcade was funded by Miguel Servet Program (CPII16/00016) (co-funded by European Social Fund, investing in your future). Alba Naudí, Manuel Portero-Otín, and Reinald Pamplona have received funding support from the Spanish Ministry of Science and Innovation (BFU2009-11879/BFI).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Valproic acid induces antioxidant effects in X-linked adrenoleukodystrophy

  • Fourcade, Stéphane
  • Ruiz, Montserrat
  • Guilera, Cristina
  • Hahnen, Eric
  • Brichta, Lars
  • Naudí i Farré, Alba
  • Portero Otín, Manuel
  • Dacremont, Georges
  • Cartier, Nathalie
  • Wanders, Ronald
  • Kemp, Stephan
  • Mandel, Jean Louis
  • Wirth, Brunhilde
  • Pamplona Gras, Reinald
  • Aubourg, Patrick
  • Pujol, Aurora
X-linked adrenoleukodystrophy (X-ALD) is a fatal, axonal demyelinating, neurometabolic disease. It results from the functional loss of a member of the peroxisomal ATP-binding cassette transporter subfamily D (ABCD1), which is involved in the metabolism of very long-chain fatty acids (VLCFA). Oxidative damage of proteins caused by excess of the hexacosanoic acid, the most prevalent VLCFA accumulating in X-ALD, is an early event in the neurodegenerative cascade. We demonstrate here that valproic acid (VPA), a widely used anti-epileptic drug with histone deacetylase inhibitor properties, induced the expression of the functionally overlapping ABCD2 peroxisomal transporter. VPA corrected the oxidative damage and decreased the levels of monounsaturated VLCFA (C26:1 n-9), but not saturated VLCFA. Overexpression of ABCD2 alone prevented oxidative lesions to proteins in a mouse model of X-ALD. A 6-month pilot trial of VPA in X-ALD patients resulted in reversion of the oxidative damage of proteins in peripheral blood mononuclear cells. Thus, we propose VPA as a promising novel therapeutic approach that warrants further clinical investigation in X-ALD., This work was supported by grants from the European Commission (LSHM-CT2004-502987 and FP7-241622), the European Leukodystrophy Association (ELA 2006-043I4), the Spanish Institute for Health Carlos III (FIS PI080991 and FIS PI051118) and the Autonomous Government of Catalonia (2009SGR85) to A.P. S.F. was a fellow of the European Leukodystrophy Association (ELA 2007-018F4). S.K. also received a grant from the European Leukodystrophy Association (ELA 2006-031I4). The work was developed under the COST action BM0604 (to A.P.). The CIBER de Enfermedades Raras is an initiative of the ISCIII. Work carried out at the Department of Experimental Medicine was supported in part by I + D grants from the Spanish Ministry of Science and Innovation (AGL2006-12433 and BFU2009-11879/BFI), the Spanish Ministry of Health (RD06/0013/0012 and PI081843), the Autonomous Government of Catalonia (2009SGR735), ‘La Caixa’ Foundation and COST B35 Action from the European Union. A.N. received a predoctoral fellowship from ‘La Caixa’ Foundation.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Oxidative stress underlying axonal degeneration in adrenoleukodystrophy: a paradigm for multifactorial neurodegenerative diseases?

  • Galea, Elena
  • Launay, Nathalie
  • Portero Otín, Manuel
  • Ruiz, Montserrat
  • Pamplona Gras, Reinald
  • Aubourg, Patrick
  • Ferrer, Isidre
  • Pujol, Aurora
X-linked adrenoleukodystrophy (X-ALD) is an inherited neurodegenerative disorder expressed as four disease variants characterized by adrenal insufficiency and graded damage in the nervous system. X-ALD is caused by a loss of function of the peroxisomal ABCD1 fatty-acid transporter, resulting in the accumulation of very long chain fatty acids (VLCFA) in the organs and plasma, which have potentially toxic effects in CNS and adrenal glands. We have recently shown that treatment with a combination of antioxidants containing α-tocopherol, N-acetyl-cysteine and α-lipoic acid reversed oxidative damage and energetic failure, together with the axonal degeneration and locomotor impairment displayed by Abcd1 null mice, the animal model of X-ALD. This is the first direct demonstration that oxidative stress, which is a hallmark not only of X-ALD, but also of other neurodegenerative processes, such as Alzheimer's disease (AD), Parkinson's disease (PD) and Huntington's disease (HD), contributes to axonal damage. The purpose of this review is, first, to discuss the molecular and cellular underpinnings of VLCFA-induced oxidative stress, and how it interacts with energy metabolism and/or inflammation to generate a complex syndrome wherein multiple factors are contributing. Particular attention will be paid to the dysregulation of redox homeostasis by the interplay between peroxisomes and mitochondria. Second, we will extend this analysis to the aforementioned neurodegenerative diseases with the aim of defining differences as well as the existence of a core pathogenic mechanism that would justify the exchange of therapeutic opportunities among these pathologies. This article is part of a Special Issue entitled: Metabolic functions and biogenesis of peroxisomes in health and disease., The work of the authors of this review was supported by grants from the European Commission (FP7-241622), the European Leukodystrophy Association (ELA2009-041D6; ELA2008-040C4), the Oliver's Army, the Spanish Institute for Health Carlos III (FIS PI080991), and the Autonomous Government of Catalonia (2009SGR85) to A.P. Centro de Investigación en Red sobre Enfermedades Raras (CIBERER) is an initiative of the Instituto de Salud Carlos III. The study was developed under the COST action BM0604 (to A.P.). Work carried out at the Department of Experimental Medicine was supported in part by R+D grants from the Spanish Ministry of Science and Innovation [BFU2009-11879/BFI], the Spanish Ministry of Health [PI081843, PI0111532], the Autonomous Government of Catalonia [2009SGR735], ‘La Caixa’ Foundation, and COST B35 Action of the European Union to M.P.O. and R.P.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Oxidative damage compromises energy metabolism in the axonal degeneration mouse model of X-Adrenoleukodystrophy

  • Fourcade, Stéphane
  • Schlüter, Agatha
  • López Erauskin, Jone
  • Guilera, Cristina
  • Jové Font, Mariona
  • Naudí i Farré, Alba
  • García Arumí, Elena
  • Andreu, Antoni L.
  • Starkov, Anatoly A.
  • Pamplona Gras, Reinald
  • Ferrer, Isidre
  • Portero Otín, Manuel
  • Pujol, Aurora
Aims: Chronic metabolic impairment and oxidative stress are associated with the pathogenesis of axonal dysfunction in a growing number of neurodegenerative conditions. To investigate the intertwining of both noxious factors, we have chosen the mouse model of adrenoleukodystrophy (X-ALD), which exhibits axonal degeneration in spinal cords and motor disability. The disease is caused by loss of function of the ABCD1 transporter, involved in the import and degradation of very long-chain fatty acids (VLCFA) in peroxisomes. Oxidative stress due to VLCFA excess appears early in the neurodegenerative cascade. Results: In this study, we demonstrate by redox proteomics that oxidative damage to proteins specifically affects five key enzymes of glycolysis and TCA (Tricarboxylic acid) cycle in spinal cords of Abcd1− mice and pyruvate kinase in human X-ALD fibroblasts. We also show that NADH and ATP levels are significantly diminished in these samples, together with decrease of pyruvate kinase activities and GSH levels, and increase of NADPH. Innovation: Treating Abcd1− mice with the antioxidants N-acetylcysteine and α-lipoic acid (LA) prevents protein oxidation; preserves NADH, NADPH, ATP, and GSH levels; and normalizes pyruvate kinase activity, which implies that oxidative stress provoked by VLCFA results in bioenergetic dysfunction, at a presymptomatic stage. Conclusion: Our results provide mechanistic insight into the beneficial effects of antioxidants and enhance the rationale for translation into clinical trials for X-adrenoleukodystrophy. Antioxid. Redox Signal. 15, 2095–2107., This study was supported by grants from the European Commission [FP7-241622], the European Leukodystrophy Association [ELA2009-036C5; ELA2008-040C4], the Spanish Institute for Health Carlos III [FIS PI080991 and FIS PI051118], and the Autonomous Government of Catalonia [2009SGR85] to A.P. The CIBER de Enfermedades Raras is an initiative of the ISCIII. The study was developed under the COST action BM0604 [to A.P.]. J. L-E. was a fellow of the Department of Education, Universities, and Research of the Basque Regional Government [BFI07.126]. S.F. was a fellow of the European Leukodystrophy Association [ELA 2007-018F4], and J.G. was a fellow of the IDIBELL program of PhD-student fellowships. Work carried out at the Department of Experimental Medicine was supported in part by R+D grants from the Spanish Ministry of Science and Innovation [AGL2006-12433 and BFU2009-11879/BFI], the Spanish Ministry of Health [RD06/0013/0012 and PI081843], the Autonomous Government of Catalonia [2009SGR735], and COST B35 Action of the European Union. The authors are indebted to Professor Isabel Fabregat for scientific discussion.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Pioglitazone halts axonal degeneration in a mouse model of X-linked adrenoleukodystrophy

  • Morató, Laia
  • Galino, Jorge
  • Ruiz, Montserrat
  • Calingasan, Noel Ylagan
  • Starkov, Anatoly A.
  • Dumont, Magali
  • Naudí i Farré, Alba
  • Martínez, Juan José
  • Aubourg, Patrick
  • Portero Otín, Manuel
  • Pamplona Gras, Reinald
  • Galea, Elena
  • Flint Beal, M.
  • Ferrer, Isidre
  • Fourcade, Stéphane
  • Pujol, Aurora
X-linked adrenoleukodystrophy is a neurometabolic disorder caused by inactivation of the peroxisomal ABCD1 transporter of very long-chain fatty acids. In mice, ABCD1 loss causes late onset axonal degeneration in the spinal cord in association with locomotor disability resembling the most common phenotype in patients, adrenomyeloneuropathy. Increasing evidence indicates that oxidative stress and bioenergetic failure play major roles in the pathogenesis of X-linked adrenoleukodystrophy. In this study, we aimed to evaluate whether mitochondrial biogenesis is affected in X-linked adrenoleukodystrophy. We demonstrated that Abcd1 null mice show reduced mitochondrial DNA concomitant with downregulation of mitochondrial biogenesis pathway driven by PGC-1α/PPARγ and reduced expression of mitochondrial proteins cytochrome c, NDUFB8 and VDAC. Moreover, we show that the oral administration of pioglitazone, an agonist of PPARγ, restored mitochondrial content and expression of master regulators of biogenesis, neutralized oxidative damage to proteins and DNA, and reversed bioenergetic failure in terms of ATP levels, NAD+/NADH ratios, pyruvate kinase and glutathione reductase activities. Most importantly, the treatment halted locomotor disability and axonal damage in X-linked adrenoleukodystrophy mice. These results lend support to the use of pioglitazone in clinical trials with patients with adrenomyeloneuropathy and reveal novel molecular mechanisms of action of pioglitazone in neurodegeneration. Future studies should address the effects of this anti-diabetic drug on other axonopathies in which oxidative stress and mitochondrial dysfunction are contributing factors., This work was supported by grants from the European Commission [FP7-241622], the European Leukodystrophy Association [ELA2009-036C5, ELA2008-040C4], the Spanish Institute for Health Carlos III [FIS PI11/01043], the Autonomous Government of Catalonia [2009SGR85 to A.P.], the Spanish Institute for Health Carlos III [Miguel Servet program CP11/ 00080 to S.F.], the COST action [BM0604 to A.P.]. S.F. was a fellow of the European Leukodystrophy Association [ELA 2010- 020F1]. L.M. is a fellow of the Spanish Ministry of Education [FPU program: AP2008-03728]. J.G. was a fellow of IDIBELL. The studies conducted at the Experimental Medicine Department were supported in part by R +D grants from the Spanish Ministry of Science and Innovation [BFU2009-11879/BFI], the Spanish Ministry of Health [PI081843], the Autonomous Government of Catalonia [2009SGR735], the ‘La Caixa’ Foundation and COST B35 Action of the European Union. The CIBER on Rare Diseases (CIBERER) and the CIBER on Neurodegenerative Diseases (CIBERNED) are initiatives of the ISCIII.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Biomarker Identification, Safety, and Efficacy of High-Dose Antioxidants for Adrenomyeloneuropathy: a Phase II Pilot Study

  • Casasnovas Pons, Carlos
  • Ruiz, Montserrat
  • Schlüter, Agatha
  • Naudi, Alba
  • Fourcade, Stéphane
  • Veciana, Misericordia
  • Castañer, Sara
  • Albertí, Antonia
  • Bargalló Alabart, Núria
  • Johnson, Maria
  • Raymond, Gerald V.
  • Fatemi, Ali
  • Moser, Ann B.
  • Villarroya i Gombau, Francesc
  • Portero-Otin, Manuel
  • Artuch Iriberri, Rafael
  • Pamplona, Reinald
  • Pujol, Aurora, 1968-
X-Adrenoleukodystrophy (X-ALD) and its adult-onset, most prevalent variant adrenomyeloneuropathy (AMN) are caused by mutations in the peroxisomal transporter of the very long-chain fatty acid ABCD1. AMN patients classically present spastic paraparesis that can progress over decades, and a satisfactory treatment is currently lacking. Oxidative stress is an early culprit in X-ALD pathogenesis. A combination of antioxidants halts the clinical progression and axonal damage in a murine model of AMN, providing a strong rationale for clinical translation. In this phase II pilot, open-label study, 13 subjects with AMN were administered a high dose of α-tocopherol, N-acetylcysteine, and α-lipoic acid in combination. The primary outcome was the validation of a set of biomarkers for monitoring the biological effects of this and future treatments. Functional clinical scales, the 6-minute walk test (6MWT), electrophysiological studies, and cerebral MRI served as secondary outcomes. Most biomarkers of oxidative damage and inflammation were normalized upon treatment, indicating an interlinked redox and inflammatory homeostasis. Two of the inflammatory markers, MCP1 and 15-HETE, were predictive of the response to treatment. We also observed a significant decrease in central motor conduction time, together with an improvement or stabilization of the 6MWT in 8/10 subjects. This study provides a series of biomarkers that are useful to monitor redox and pro-inflammatory target engagement in future trials, together with candidate biomarkers that may serve for patient stratification and disease progression, which merit replication in future clinical trials. Moreover, the clinical results suggest a positive signal for extending these studies to phase III randomized, placebo-controlled, longer-term trials with the actual identified dose. ClinicalTrials.gov Identifier: NCT01495260.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Impaired mitochondrial oxidative phosphorylation in the peroxisomal disease X-linked adrenoleukodystrophy

  • López Erauskin, Jone
  • Galino, Jorge
  • Ruiz, M.
  • Cuezva, J. M.
  • Fabregat, I.
  • Cacabelos Barral, Daniel
  • Boada Pallàs, Jordi
  • Martínez, Juan José
  • Ferrer, Isidre
  • Pamplona Gras, Reinald
  • Villarroya, Francesc
  • Portero Otín, Manuel
  • Fourcade, Stéphane
  • Pujol, Aurora
X-linked adrenoleukodystrophy (X-ALD) is an inherited metabolic disorder of the nervous system characterized by axonopathy in spinal cords and/or cerebral demyelination, adrenal insufficiency and accumulation of very long-chain fatty acids (VLCFAs) in plasma and tissues. The disease is caused by malfunction of the ABCD1 gene, which encodes a peroxisomal transporter of VLCFAs or VLCFA-CoA. In the mouse, Abcd1 loss causes late onset axonal degeneration in the spinal cord, associated with locomotor disability resembling the most common phenotype in patients, adrenomyeloneuropathy. We have formerly shown that an excess of the VLCFA C26:0 induces oxidative damage, which underlies the axonal degeneration exhibited by the Abcd1− mice. In the present study, we sought to investigate the noxious effects of C26:0 on mitochondria function. Our data indicate that in X-ALD patients' fibroblasts, excess of C26:0 generates mtDNA oxidation and specifically impairs oxidative phosphorylation (OXPHOS) triggering mitochondrial ROS production from electron transport chain complexes. This correlates with impaired complex V phosphorylative activity, as visualized by high-resolution respirometry on spinal cord slices of Abcd1− mice. Further, we identified a marked oxidation of key OXPHOS system subunits in Abcd1− mouse spinal cords at presymptomatic stages. Altogether, our results illustrate some of the mechanistic intricacies by which the excess of a fatty acid targeted to peroxisomes activates a deleterious process of oxidative damage to mitochondria, leading to a multifaceted dysfunction of this organelle. These findings may be of relevance for patient management while unveiling novel therapeutic targets for X-ALD., This study was supported by grants from the European Commission (FP7-241622), the European Leukodystrophy Association (ELA2009-036C5; ELA2008-040C4), the Spanish Institute for Health Carlos III (FIS PI080991 and FIS PI11/01043), the Autonomous Government of Catalonia (2009SGR85) to A.P. and the Spanish Institute for Health Carlos III (Miguel Servet program CP11/00080) to S.F. The CIBER on Rare Diseases (CIBERER) is an initiative of the ISCIII. The study was developed under the COST action BM0604 (to A.P.). J.L.-E. was a fellow of the Department of Education, Universities and Research of the Basque Country Government (BFI07.126). S.F. was a fellow of the European Leukodystrophy Association (ELA 2010-020F1). The studies conducted at the Department of Experimental Medicine were supported in part by R&D grants from the Spanish Ministry of Science and Innovation (BFU2009-11879/BFI), the Spanish Ministry of Health (PI11/ 1532), the Autonomous Government of Catalonia (2009SGR735), the ‘La Caixa’ Foundation and COST B35 Action of the European Union. D.C. is a fellow from the Spanish Ministry of Health (FI08-00707). The studies conducted at the Department of Biochemistry and Molecular Biology, University of Barcelona, were supported by grants SAF2008-01896 and SAF2011-23636 from the Spanish Ministry of Science and Innovation. The CIBER in Physiopathology of Obesity and Nutrition (CIBERobn) is an initiative of the ISCIII.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Activation of sirtuin 1 as therapy for the peroxisomal disease adrenoleukodystrophy

  • Morató, Laia
  • Ruiz, M.
  • Boada Pallàs, Jordi
  • Calingasan, Noel Ylagan
  • Galino, Jorge
  • Guilera, Cristina
  • Jové Font, Mariona
  • Naudí i Farré, Alba
  • Ferrer, Isidre
  • Pamplona Gras, Reinald
  • Serrano, M.
  • Portero Otín, Manuel
  • Beal, M. F.
  • Fourcade, Stéphane
  • Pujol, Aurora
Oxidative stress and mitochondrial failure are prominent factors in the axonal degeneration process. In this study, we demonstrate that sirtuin 1 (SIRT1), a key regulator of the mitochondrial function, is impaired in the axonopathy and peroxisomal disease X-linked adrenoleukodystrophy (X-ALD). We have restored SIRT1 activity using a dual strategy of resveratrol treatment or by the moderate transgenic overexpression of SIRT1 in a X-ALD mouse model. Both strategies normalized redox homeostasis, mitochondrial respiration, bioenergetic failure, axonal degeneration and associated locomotor disabilities in the X-ALD mice. These results indicate that the reactivation of SIRT1 may be a valuable strategy to treat X-ALD and other axonopathies in which the control of redox and energetic homeostasis is impaired., This work was supported by grants from the European Commission [FP7-241622], the Spanish Institute for Health Carlos III [FIS PI11/01043], the Oliver’s Army Foundation, the Government of Catalonia [2009SGR85 to AP], the Spanish Institute for Health Carlos III [Miguel Servet program CP11/00080 to S.F.], the European Leukodystrophy Association (ELA) [ELA 2010-020F1 to SF, ELA 2013-003F1 to LM], the Spanish Ministry of Education [FPU program AP2008-03728 to LM]. JG held an IDIBELL PhD fellowship. The studies conducted at the Experimental Medicine Department were supported in part by R+D grants from the Spanish Ministry of Science and Innovation [BFU2009-11879/BFI], the Spanish Ministry of Health [PI081843, PI1300584], the Government of Catalonia [2009SGR735], the 'La Caixa' Foundation and COST B35 Action of the European Union. CIBERER and CIBERNED are initiatives of the Spanish Institute for Health Carlos III.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Altered glycolipid and glycerophospholipid signaling drive inflammatory cascades in adrenomyeloneuropathy

  • Ruiz, Montserrat
  • Jové Font, Mariona
  • Schlüter, Agatha
  • Casasnovas, Carlos
  • Villarroya, Francesc
  • Guilera, Cristina
  • Ortega, Francisco J.
  • Naudí i Farré, Alba
  • Pamplona Gras, Reinald
  • Gimeno, Ramón
  • Fourcade, Stéphane
  • Portero Otín, Manuel
  • Pujol, Aurora
X-linked adrenomyeloneuropathy (AMN) is an inherited neurometabolic disorder caused by malfunction of the ABCD1 gene, characterized by slowly progressing spastic paraplegia affecting corticospinal tracts, and adrenal insufficiency. AMN is the most common phenotypic manifestation of adrenoleukodystrophy (X-ALD). In some cases, an inflammatory cerebral demyelination occurs associated to poor prognosis in cerebral AMN (cAMN). Though ABCD1 codes for a peroxisomal transporter of very long-chain fatty acids, the molecular mechanisms that govern disease onset and progression, or its transformation to a cerebral, inflammatory demyelinating form, remain largely unknown. Here we used an integrated -omics approach to identify novel biomarkers and altered network dynamic characteristic of, and possibly driving, the disease. We combined an untargeted metabolome assay of plasma and peripheral blood mononuclear cells (PBMC) of AMN patients, which used liquid chromatography coupled to quadrupole-time-of-flight mass spectrometry (LC-Q-TOF), with a functional genomics analysis of spinal cords of Abcd1− mouse. The results uncovered altered nodes in lipid-driven proinflammatory cascades, such as glycosphingolipid and glycerophospholipid synthesis, governed by the β-1,4-galactosyltransferase (B4GALT6), the phospholipase 2γ (PLA2G4C) and the choline/ethanolamine phosphotransferase (CEPT1) enzymes. Confirmatory investigations revealed a non-classic, inflammatory profile, consisting on the one hand of raised plasma levels of several eicosanoids derived from arachidonic acid through PLA2G4C activity, together with also the proinflammatory cytokines IL6, IL8, MCP-1 and tumor necrosis factor-α. In contrast, we detected a more protective, Th2-shifted response in PBMC. Thus, our findings illustrate a previously unreported connection between ABCD1 dysfunction, glyco- and glycerolipid-driven inflammatory signaling and a fine-tuned inflammatory response underlying a disease considered non-inflammatory., We are indebted to Dr Arndt G. Benecke for critically reading the manuscript. This study was supported by grants from the Hesperia Foundation, the Asociación Española contra las Leucodistrofias (ALE-ELA España), the Spanish Ministry for Health and Social Policy (MSPSI EC10-137), the European Commission (FP7- 241622), the Spanish Institute for Health Carlos III and ‘Fondo Europeo de Desarrollo Regional (FEDER), Unión Europea, una manera de hacer Europa’ (FIS PI11/01043, FIS PI14/00410, FIS ICI14/00076), and the Autonomous Government of Catalonia AGAUR (2009SGR85, 2014SGR1430 to A.P.); the Spanish Institute for Health Carlos III and ‘Fondo Europeo de Desarrollo Regional (FEDER), Unión Europea, una manera de hacer Europa’ (FIS PI14/ 00581) to C.C. and the Spanish Institute for Health Carlos III Miguel Servet program CP11/00080 to S.F. The studies conducted at the Department of Experimental Medicine were supported in part by R+D grants from the Spanish Ministry of Science and Innovation (BFU2009-11879/BFI), the Spanish Ministry of Health (PI111543; PI1300584, PI140115), the Autonomous Government of Catalonia (2009SGR735), the ‘La Caixa’ Foundation, and COST B35 The CIBER on Rare Diseases (CIBERER) and on Physiopathology of Obesity and Nutrition (CIBEROBN) are initiatives of the ISCIII.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Autophagy induction halts axonal degeneration in a mouse model of x-adrenoleukodystrophy

  • Launay, Nathalie
  • Aguado, Carmen
  • Fourcade, Stéphane
  • Ruiz, Montserrat
  • Grau, Laia
  • Riera, Jordi
  • Guilera, Cristina
  • Giròs, Marisa
  • Ferrer, Isidro (Ferrer Abizanda)
  • Knecht, Erwin
  • Pujol Onofre, Aurora
X-linked adrenoleukodystrophy (X-ALD) is a rare neurometabolic disease characterized by the accumulation of very long chain fatty acids (VLCFAs) due to a loss of function of the peroxisomal transporter ABCD1. Here, using in vivo and in vitro models, we demonstrate that autophagic flux was impaired due to elevated mammalian target of rapamycin (mTOR) signaling, which contributed to X-ALD pathogenesis. We also show that excess VLCFAs downregulated autophagy in human fibroblasts. Furthermore, mTOR inhibition by a rapamycin derivative (temsirolimus) restored autophagic flux and inhibited the axonal degenerative process as well as the associated locomotor impairment in the Abcd1 (-) /Abcd2 (-/-) mouse model. This process was mediated through the restoration of proteasome function and redox as well as metabolic homeostasis. These findings provide the first evidence that links impaired autophagy to X-ALD, which may yield a therapy based on autophagy activators for adrenomyeloneuropathy patients.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Tauroursodeoxycholic bile acid arrests axonal degeneration by inhibiting the unfolded protein response in X-linked adrenoleukodystrophy

  • Launay, Nathalie|||0000-0002-7498-217X
  • Ruiz, Montserrat|||0000-0003-0466-2653
  • Grau-López, Laia|||0000-0002-5272-0806
  • Ortega, Francisco|||0000-0003-0039-1593
  • Ilieva, Ekaterina V.
  • Martínez, Juan José
  • Galea, Elena|||0000-0003-4537-9897
  • Ferrer, Isidro|||0000-0001-9888-8754
  • Knecht, Erwin
  • Pujol, Aurora|||0000-0002-9606-0600
  • Fourcade, Stéphane|||0000-0002-8031-5007
The online version of this article (doi:10.1007/s00401-016-1655-9) contains supplementary material, which is available to authorized users.